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Abstract
Background: Prevention of colorectal cancer is a major health care issue. People who have undergone
colonoscopy screening and had colorectal polyps removed have a higher risk of being diagnosed with polyps
again compared to the normal population. Therefore, it would be ideal to find appropriate means that effectively
help to prevent the reoccurrence of polyps after polypectomy. So far, pharmaceutical chemoprevention with
NSAIDs including aspirin has been shown to be effective but not gained general acceptance due to side effects.
Nutraceuticals such as polyphenols from tea plants have demonstrated remarkable therapeutic and preventive
effects in molecular, epidemiological and clinical trials. However, placebo-controlled trials demonstrating the
efficacy of nutraceuticals for the (secondary) prevention of colorectal polyps as precursors for colorectal cancer are
missing.
Methods/Design: We present the design of a randomized, placebo controlled, multicentre trial to investigate the
effect of diet supplementation with green tea extract containing 300 mg epigallocatechin gallate (EGCG), the major
polyphenol in green tea, on the recurrence of colon adenomas. Patients who have undergone polypectomy for
colonic polyps will be randomized to receive either green tea extract containing 150 mg EGCG two times daily or
a placebo over the course of three years. After a one month run-in period in which all patients will receive the
active intervention, 2534 patients will be randomized, and 2028 patients are expected to complete the whole
study course. Incidence, number and histology of adenoma at endpoint colonoscopy at three years will be
compared in both groups.
Discussion: The beneficial safety profile of decaffeinated green tea extract, the quantifiable and known active
content EGCG, and the accumulating evidence of its cancer preventive potential require, in our view, a validation
of this compound for the nutriprevention of colorectal adenoma. Good accessibility and low costs might render
this neutraceutical a top candidate for wider use as food supplement in colon cancer prevention.
Trial registration: ClinicalTrials.gov: NCT01360320
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The use of nutritional compounds for disease prevention
and health maintenance is an emerging field, since nutri-
tional products are usually less afflicted with the risk of
severe side effects, and long-term experience in humans
exists. Especially for cancer prevention, associations
between diet and lifestyle have been established [1].
Green tea belongs to the oldest drinks of mankind,
and its high levels of bioactive polyphenols provide the
potential for therapeutic and preventive application.
Supplementation of diet with green tea polyphenols as a
nutraceutical has already been studied in the context of
cancer, diabetes and cardiovascular disease [2-7].
About 30% of the content of green tea is polyphenols.
The monomer flavan-3-ols are called catechins, and
contribute to the astringent/bitter taste of green tea.
Among all catechins in green tea the most important
are 59% (-)-epigallocatechin-3-gallate (EGCG), 19%
(-)-epigallocatechin (EGC), 13.6% (-)-Epicatechin-3-gal-
late (ECG), and 6.4% (-)-epicatechin (EC) [8].
Due to its presumed beneficial effects on cancer initia-
tion and early cancer progression green tea polyphenols
might be especially suited for cancer prevention rather
than for cancer treatment [9]. The majority of colorectal
cancers, the most frequent cancer type in men, shows a
slow progression from normal mucosa to adenoma or
advanced lesion (adenoma-carcinoma sequence), there-
fore allowing efforts for prevention of colorectal cancer
[10]. Several studies on the chemoprevention of colorec-
tal cancer have been performed using compounds such
as acetyl salicylic acid (ASS) or cyclooxygenase (COX)
isoenzyme 2-specific nonsteroidal anti-inflammatory
agents (NSAIDs) [11-17]. NSAIDs seem to have a bene-
ficial effect in preventing the development and/or recur-
rence of adenomas. However, the benefit risk ratio of
daily use of these agents over years does not seem to
justify a broad use for primary or secondary chemopre-
vention due to adverse effects such as gastrointestinal
hemorrhage, peptic ulcers and potential cardiovascular
toxicity [18]. Therefore, COX inhibitors have been
accepted as chemopreventive agents only for patients
with a very high risk of developing colorectal cancer,
such as those with familial adenomatous polyposis [19].
Green tea extract and its major active component
EGCG have been studied in several models for their
preventive properties on the development of colon ade-
nomas. In the Apc
min mouse, a model for colon ade-
noma development, a tremendous effect on the number
and growth of adenomas was detected upon feeding the
animals with EGCG-supplemented drinking water
[20,21].
In addition, EGCG even inhibits the growth of estab-
lished human colorectal cancer cells and induces
apoptosis, which is accompanied by inhibition of COX-2
expression and reduced activation of the epidermal
growth factor receptor tyrosine kinase family [22,23].
One small pilot study on the supplementation of green
tea consumption with capsules containing green tea
extract in Japanese patients with a history of colon ade-
nomas resulted in a 50% reduction of the incidence of
metachronous adenomas in the supplementation group
compared to the placebo group after one year [9]. Epi-
demiological studies in Asian countries also point to a
preventive effect on colon cancer from high daily intake
of green tea (more than 5 cups daily) [24,25].
Since green tea extract - in contrast to green tea itself
- is decaffeinated, diet supplementation with EGCG
from green tea extract may constitute a nutriprevention
with an extremely favorable safety profile. We report
here on the design of a large, placebo-controlled pro-
spective trial on the effect of diet supplementation with
EGCG on colorectal adenoma prevention.
Methods/Design
Design and setting
The trial follows a prospective randomized controlled
design comparing the twice daily intake of green tea
extract containing 150 mg EGCG supplement to a pla-
cebo. Patients will be randomized after a verum run-in
period of one month to receive either green tea extract
containing 150 mg EGCG two times daily or placebo
over the course of three years.
Study outcomes
Primary outcome
The primary outcome parameter will be the incidence of
any (n equal to or larger than 1) metachronous colorec-
tal adenomas (tubulovillous, tubular, villous and serrated
lesions) at the 3 year follow-up colonoscopy in both
groups.
Secondary outcomes
The occurrences, number, localization, size and histolo-
gical subtypes of adenomas or mucosal lesions and inva-
sive growth, as well as the time to detection of new
colorectal carcinoma (assuming that in several patients
more than one colonoscopy will be performed within 3
years) and the frequency of carcinoma, will be assessed
as secondary outcome parameters in both groups. In
addition, genetic and biochemical biomarkers for the
recurrence of adenoma or the development of dysplasia
and carcinoma will be analyzed in the blood samples
entered into the biobanking subproject. Paraffin-
embedded tissue samples will be collected in partici-
pants who show a high grade dysplastic adenoma or ser-
rated adenoma at the follow-up colonoscopy. In these
samples, besides the histological analyses the possibly
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including K-ras mutation, B-raf mutation or specific
microRNA will be analyzed.
In an independent project, the nutrikinetics and nutri-
genetics of EGCG and other green tea catechins will be
assessed in healthy volunteers with the capsules used in
this study.
Sample size calculation
The sample size estimation was derived from the exist-
ing chemopreventive studies reporting a re-incidence of
metachronous adenomas of about 45% at follow-up
colonoscopy [13]. Assuming an effect similar to that
observed for ASS, chemoprevention might lead to a
relative risk reduction of 12% [13]. Therefore, if ECGC
intake leads to a similar relative risk reduction of 11%
and if there is a recurrence of adenomas in 45% of the
patients in the placebo group, 40% of the patients taking
green tea extract should have a recurrent adenoma after
three years. Sample size estimation was performed using
the Mantel-Haenszel test stratifying for the use of low-
dose ASS, assuming that 20% of the study participants
will be on low-dose (≤ 100 mg) ASS due to the frequent
use of low-dose ASS in the age group of the participants
(50 years and above). Assum i n gar e c u r r e n c er a t eo f
38.3% in the combined verum green tea and low-dose
ASS arm, and of 47.1% in the placebo/no ASS group, a
sample size of n = 1203 (both in verum and placebo) is
required for the intention to treat (ITT) sample with
significance level of 5% and a power of 80% (stratified
one-sided Mantel-Haenszel test, NQUERY 7.0 software,
Statistical Solutions, Cork, Ireland).
A s s u m i n gad r o p - o u tr a t eo f5 %o fp a t i e n t sf o rt h e
control colonoscopy, 1267 randomized patients per arm
will be required, resulting in randomization of 2534
patients after the run-in period.
A drop-out rate of 20% is assumed for regular capsule
intake. Thus, 1014 patients will be evaluable for the per-
protocol analysis of the green tea effect. For exploratory
analysis of potential confounders, this sample size is suf-
ficient to include 30-40 variables inclusive dummy-cod-
ing with around 20 events per variable into the model.
Participants
The study will be performed nationwide in Germany.
Patients will be recruited from gastroenterological cen-
ters that are performing a high number of screening and
interventional colonoscopies. Participants undergoing
screening colonoscopy who are diagnosed with colorec-
tal adenomas will be randomized within 6 months after
polypectomy if they give informed consent. Participants
who are willing to participate in the trial will undergo a
short screening interview and then enter the run-in
phase of 4 weeks, in which all participants of the trial
will receive verum. This run in-phase is designed to
obtain information about potential and unforeseen side
effects of green tea extract intake that might affect the
well-being of the participants or the blinding of the trial.
Randomization will follow after a successful run-in per-
iod. Participants who are not compliant to the study
protocol or do not tolerate the green tea extract supple-
mentation will not be randomized.
As judged from similar trials, we expect a 15% drop-
out rate after run-in. Thus, 2941 participants will be
included in the run-in phase in order to achieve a total
number of 2534 randomized participants (Figure 1).
In Germany, about 500,000 individuals undergo
screening colonoscopies each year. A large colonoscopy
center typically performs more than 3000 colonoscopies
per year. In 10-15% of these screenings, adenomas are
detected and removed. We expect that about half of
these cases will be eligible for study inclusion. About 30
colonoscopy centers will take part in this study, in order
to allowing us to recruit the planned number of partici-
pants in the intended 3-year period.
Inclusion & exclusion criteria
Interested persons are eligible for study participation if
they are between 50-80 years of age, and have had histo-
logically confirmed colorectal adenomas or serrated
lesions removed during colonoscopy within the last 6
months. All participants of the study must be in good
performance status at study entrance, corresponding to
a level below 2 in the ECGG performance status scale
[26]. Only patients able to give informed consent will be
included after written informed consent.
Exclusion criteria for study participation are a history
of hereditary nonpolyposis colorectal cancer (HNPCC)
or familial adenomatous polyposis (FAP), a history of
colorectal cancer or other concomitant cancers with the
exception of basal cell carcinoma or curative treated
cancers without actual anticancer medication. In addi-
tion, interested parties with intestinal malabsorption,
short bowel syndrome or surgical bowel interventions
leading to malabsorption will not be included into the
study. Liver failure (hepatitis, cirrhosis), elevation of the
liver enzymes ALT, AST or bilirubin to more than 2.5-
fold above the upper normal value or inflammatory
bowel disease are also exclusion criteria.
Regular intake of NSAIDs (including Cox-2 inhibitors)
for more than 3 months per year, with the exception of
low-dose ASS (≤ 100 mg per day), is not compatible
with study participation. In addition, individuals who are
on immunosuppressive medication are excluded from
the study.
Individuals with impaired capacity to consent or who
are impaired in swallowing pills will not be eligible for
study participation.
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green tea extract with an EGCG content of more than
100 mg per day as a nutritional supplement for more
than six months during the past two years will be
excluded, as will individuals who have shown allergic
reactions to green tea or its extract.
Patient information and allocation
Informed consent is obtained after written and oral
information by a study physician prior to inclusion into
the study. The potential participants must fully under-
stand all possible implications of the study, and all their
questions must be answered sufficiently. After written
informed consent, participants will be included into the
one month run-in period where all participants receive
2×1 5 0m gE G C Gd a i l yo v e r4w e e k s .A ts t u d yi n c l u -
sion and after this period, liver enzymes (AST, ALT,
bilirubin) will be checked and patients who either have
more than 20 capsules (out of 64) left or have elevated
liver enzymes of more than 2.5-fold of the upper normal
value will be excluded from the study.
After the one month run-in period with ECGC,
patients will be assessed and randomized to either the
intervention group, which will receive green tea extract
containing 300 mg EGCG per day, or to the control
group, which will receive a placebo capsule twice daily.
Blinding and randomization
Stratified randomization based on study centers and on
regular intake of low-dose ASS (yes or no) will be
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Patients who underwent 
colonoscopy with extirpation 
of adenoma:  
n>4000 
Run-In 
N=2941 
Patients not interested or not 
admitted due to exclusion criteria 
Subjects randomized 
for placebo n=1267 
15% Dropout  
Follow-up colonoscopy after 
three years n=1203 
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n=64 
 
Adherent subjects at 
follow-up colonoscopy: 
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20% Dropout: 
nonadherence n=253 
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three years n=1203 
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  Adherent subjects at 
follow-up colonoscopy: 
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Subjects randomized for GTE 
n=1267 
Figure 1 Flow Diagram of the progress through the phases of the study. Assuming a drop-out rate of 5% of patients for the control
colonoscopy, 1267 randomized patients per arm will be required, resulting in randomization of 2534 patients after the run-in period. 1203
patients per arm are expected to be available for the ITT analysis undergoing control colonoscopy after three years. A drop-out rate of 20% is
assumed for regular capsule intake. Thus, 1014 patients will be evaluable for the per-protocol analysis of the green tea effect.
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ance of these baseline covariates. There will be no
further stratification, since it is assumed that with a
sample size of n = 1203 per group for the ITT collec-
tive, covariates like green tea consumption, age, sex,
family history of colon cancer, medication and lifestyle
will be equally distributed in both study arms.
Recruitment will be competitive and concurrent in
about 30 colonoscopy screening centers throughout
Germany. It will be assumed that each study center will
recruit at least 30 patients per year.
Patients and physicians including the study coordina-
tors will be fully blinded to the study substance. An
independent pharmaceutical contract manufacturer spe-
cializing in solid pharmaceutical dosing forms will pro-
duce the placebo and EGCG capsules, and will dispense
them according to a randomization list. Patients
included into the run-in phase will be notified by a fax
to the study coordinating center.
Randomization will take place after a successful run-in
period, and a random study number will be assigned to
each participant. The study substance for the first three
months (three packages containing 70 blistered capsules
each) will then be sent out during one week after the
end of the run-in period. Study start is the first day of
intake of the study substance.
Study procedures
Green tea extract
Powdered decaffeinated green tea extract will be pre-
pared from the young unfermented leaf and leaf buds of
Camellia Sinensis (L.) Kuntze (Fam. Theaceae) imported
from China. The normally associated caffeine found in
lower grade tea catechin mixtures will be eliminated to
less than 0.5% content in the extract. The extract will be
prepared using ethanol, methanol, acetone or water, as
solvents. Microbiological and toxicological analyses are
done to control for degradation products, pesticides,
herbicides, polyaromatic hydrocarbons, and other unac-
ceptable contaminants.
The study material will be packed in hard gelatine
capsules containing either green tea extract (150 mg
EGCG) or placebo, and pharmaceutical excipients con-
sisting of microcrystalline cellulose, colloidal silicon
dioxide, and magnesium stearate. The caffeine content
of the green tea extract used to prepare the capsules
will be maximally 0.5% and thus the caffeine content of
one capsule will be below 1.5 mg.
Dose determination
The application of green tea extract standardized to a
twice daily dose of 150 mg EGCG was decided upon a
review of the existing literature on clinical long-term
prevention studies and the rationale that a nutripreven-
tion study should involve doses corresponding to nutri-
tional use of green tea for which there is at least some
epidemiological evidence for a cancer-preventive action.
A simple calculation shows that a daily dose of 300
mg EGCG corresponds to a normal intake of green tea:
one cup of green tea is brewed with approximately 2 g
of tea leaves. Tea leaves have a catechin content of
about 10%. If the tea is brewed for 10 min, about 80%
of the catechins will have dissolved. The amount of
EGCG is about 50% of the catechins. This means that
one cup of this green tea would contain about 80 mg
EGCG, and the same amount of other dissolved cate-
chins. Thus, 300 mg would correspond to 4 cups of tea
brewed with this method. In practice, tea may be
brewed with a shorter duration, which would result in a
lower concentration of catechins. Thus, the daily dose
applied in this study certainly lies within the range of 4-
7 cups of tea per day, which is still a physiological dose.
A check with the literature reveals that in all existing
long term studies, similar doses have been given (see
table 1).
Side effects and contraindications
There are no known common side effects of green tea
extract. A systematic review performed in 2008 by the
United States Pharmacopeia, case reports and animal
pharmacology/toxicology studies from 1966 to 2007
showed no clear evidence for EGCG-related toxicity,
specifically liver enzyme elevation in a common dose
range of up to 800 mg [28]. A total of 216 case reports
on green tea products were analyzed, including 34
reports concerning liver damage. Twenty-seven reports
Table 1 summary of long term (≥ 2 weeks) interventional studies with green tea extract
Study Daily intake of EGCG Duration of trial Sample size Total catechins EGCG ECG EGC EC Caffeine
[38] 300 mg 12 months 60 76% 52% 6% 6% 12% 0.1%
[7] 350 mg 2 months 69 84% Not specified 19%
[31] 800 mg 1 month 8 98% 70% 13% 11%
[9] 150 mg 12 months 71 20% 11% 2% 7% 0.2% 3%
[39] 225 mg 3 months 64 100% 35% 17% < 1% < 1% 7%
[40] 800 mg 1 month 26 80%-98% 50-75% 12% 2%
[6] 2000 mg 6 months 5 98% 70% 13% 11%
[2] 300 mg 2 weeks 42 100% 100%
Stingl et al. BMC Cancer 2011, 11:360
http://www.biomedcentral.com/1471-2407/11/360
Page 5 of 9pertaining to liver damage were categorized as possible
causality and seven as probable causality [28]. Consump-
tion of concentrated green tea extract on an empty sto-
mach is more likely to lead to adverse effects than
consumption in the fed state, since up to five-fold
higher plasma concentrations have been observed with
empty stomach compared to the fed state [29-31]. In
our study, liver enzyme parameters will be tested prior
to enrollment, after the one month run-in period and
after 4, 12, 20 and 36 months, respectively. An increase
of liver enzymes by 2.5-fold above the upper normal
value will lead to discontinuation of the study medica-
tion. Participants will be urged to take the capsules at
breakfast and dinner. There are no known contraindica-
tions for the intake of green tea extract. Nevertheless,
we will test for hepatotoxicity after one month of EGCG
intake.
Interactions
The potential of EGCG to induce drug-drug interactions
by the inhibition of major human cytochrome P450 iso-
enzymes has been studied in vitro using isoform-selec-
tive probe substrates for the major human CYP450
isoforms involved in drug-metabolism (CYP1A2, 2C9,
2C19, 2D6 and 3A4) [32]. Based on these in vitro
results, no significant interactions are expected in man
for EGCG with concomitantly administered compounds
mainly metabolized by CYP1A2, CY2C9, CYP2C19,
CYP2D6 and CYP3A4. Interactions via inhibition of
transporters such as P glycoprotein or Multidrug Resis-
tance Protein (MRP) by EGCG is possible, but has not
been reported so far.
Study visits
Every four months during the 36 months of the whole
study, the participants will be asked to visit the gastro-
enterological centers to check for any adverse events
and medication changes, and to confirm with the physi-
cian the regular intake of the study medication. Blood
sampling for liver enzyme testing will be performed
after run in, and at the 4, 12, 20 and 36 month visits,
and at 4, 20 and 36 months for biomarker sampling.
Data on health status, medication, and complaints
about the study substance will be collected and the
study diary will be reviewed. After each clinical visit, the
study medication for the next study period will be dis-
pensed. In cases of non-compliance or any disruption
longer than four months of intake of EGCG, the study
investigators will decide whether the participant may
continue in the study.
The final study visit will be for the control colono-
scopy three years after the start of the study. If addi-
tional colonoscopies have been performed during the
three year interval, the results of those will be
documented as well. The results of the colonoscopy as
well as the histological confirmation of potential meta-
chronous colorectal adenomas will be documented, as
well as clinical data on medication, health status, com-
plaints and adherence to capsule intake.
Follow-up visits are planned for three and six years
after the end of the study in order to assess the long
term development of adenoma ss i n c ew ek n o wt h a ti t
may take years to see the effect of a preventive treat-
ment. As an example, the effect of ASS chemopreven-
tion on colon carcinoma was assessed 10 years after
[33].
Drop-out criteria
In the following situations, no study enrollment after the
run-in is foreseen:
￿ If the pill count after the run-in period contains
more than 30 capsules (out of 70 capsules).
￿ If the liver enzyme parameters are elevated above
2.5-fold of the upper normal value.
￿ Study participation will be terminated in the fol-
lowing occasions:
￿ in the case of any severe adverse event impairing
further participation in the study
￿ If the adherence to study medication is poor (if >
35% of the capsules were not taken during more
than one study period)
￿ the regular intake of the capsules is not assured,
for any reason
￿ it becomes evident after the enrollment that the
inclusion criteria have not been fulfilled
￿ a continuous (longer than 3 months) intake of the
following drugs has become necessary: Any NSAID
including COX-2 selective NSAIDs and ASS in a
dose higher than 100 mg
￿ the patients desires to exit the study
￿ The liver enzyme parameters are elevated more
than 2.5-fold of the upper normal value.
It is intended to include the data of the follow-up
colonoscopy in the subjects that have dropped out for
the intention-to-treat analysis.
Biobanking
At time points prior to the run-in period, and after 4, 20
and 36 months, blood sampling for biobanking will be
performed. The biobank will consist of pseudonymized
(coded) plasma, serum and whole blood samples for bio-
markers for adenoma development, as well as paraffin
blocks of advanced adenomas detected in study partici-
pants at the 3 year colonoscopy. Participation in the
clinical trial is independent from the biobanking project,
and thus, separate informed consent will be given for
the biobanking project.
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The MIRACLE study will be performed according to the
study protocol, as well as the ICH-GCP criteria, the
Declaration of Helsinki, EU directives and applicable
legal requirements. The study has been approved by
Ethical Review Boards of the Martin Luther University
of Halle-Wittenberg and Ulm University (Application
68/09, approved on the 9th of April 2009).
Data collection
Information on each patient’s age, gender, height,
weight, waist-to-hip ratio, ethnicity, regular tea intake,
sport and activity level, smoking state, alcohol intake,
family history of colon cancer and current disease and
medication will be obtained from the initial interview
before the run-in phase. From the colonoscopy prior to
study entry, data on the number, localization and size of
the removed adenoma(s) as well as the histological sub-
type and history of prior colonoscopies will be assessed.
The patients’ attitudes towards medicine and herbal
supplements will be assessed at the beginning of the
study.
At the follow-up visits, data on changes in concurrent
disease or drug therapy, data on regular intake of the
study medication and green tea beverages, laboratory
data on liver enzymes and any adverse events experi-
enced during the study will be recorded.
At the final visit, weight, waist-to-hip ratio, regular tea
intake, data on changes in disease and medication will
be obtained as well as data from the follow-up colono-
scopy on the number, localization and size of the
removed adenoma(s) as well as the histological subtype.
Data management
Data management, query management and monitoring
of the study will be done by the Coordination Center
for Clinical Trials at the Martin Luther University of
Halle-Wittenberg (KKSH). Data collection will be done
on paper CRFs and will be entered and stored in a vali-
dated GCP conform database. Study monitoring will be
performed with one on-site visit per study center and
regular data-entry checks of the CRFs.
Statistical analysis
The trial results will be analyzed by intention-to-treat
and the per-protocol analysis. In analogy to [15] a modi-
fied intention-to-treat approach will be performed
including all randomized subjects with a follow-up colo-
noscopy, irrespective of adherence to the study medica-
tion. Lacking values will be estimated using the Multiple
Imputation MCMC method [34].
T h ep e r - p r o t o c o la n a l y s i sw i l lb ed o n ei na l ls u b j e c t s
who completed the whole course of the study. Safety
will be assessed in all patients who took at least one
capsule of the study medication.
Statistical analysis of the primary outcome The
study’s aim is to check the following hypothesis: the
regular intake of green tea extract (at least 300 mg
daily) over three years results in a decrease of the inci-
dences of colorectal adenomas. This primary outcome
based on the intention-to-treat-population will be tested
confirmatively by the one-sided c
2-Test [35] with a sig-
nificance level of 5%.
The impact of other variables (e. g. study center,
intake of low-dose ASS) related to the recurrence of
adenomas will be explorative controlled by the logistic
regression model [36]. Concerning the time of the
recurrence of adenomas, the impact of other variables
will be explorative controlled with the Cox proportional
hazard model [37].
With the help of this multivariate analysis both the
relative risks and the 95% confidence-intervals can be
calculated.
Statistical analyses of the secondary outcome How
much other impact factors affect the risk of the inci-
dence of metachronous adenomas will be analyzed
explorative.
In addition, genetic and biochemical biomarkers for
the recurrence of adenomas or the development of dys-
plasia and carcinoma will be analyzed explorative in the
blood samples entered into the biobanking subproject.
Time plan
Patient recruitment is planned for a period of three
years starting in October 2011. The total duration of the
trial will be six years, with the last patient out in fall
2017.
Discussion
The aim of this large prevention trial is to study the
influence of regular nutritional supplementation with
green tea extract containing EGCG, one of the active
components of green tea, on the incidences of meta-
chronous colorectal adenomas in subjects who have
undergone polypectomy. Thus, it is a secondary preven-
tion trial
The limitation of prior large-scale chemoprevention
trials, when administering drugs like ASS or COX-2
inhibitors to a large group of healthy individuals for
long term treatment, was safety. Even if the trials were
successful with respect to their primary endpoint, pre-
vention of metachronous colorectal adenomas, the clini-
cal utility of NSAIDs used for this indication is rather
low due to the unwanted side effects of these drugs.
This is the first large-scale controlled prevention trial
using nutritional supplement as the active principle. The
dose of ECGC in our green tea extract was chosen to
mimic high and regular green tea consumption without
the influence of caffeine. While we are aware that 300
mg ECGC per day is lower than the dose range in some
trials (with multiple dose data of up to 800 mg per day),
w ec h o s et h i sd o s eb e c a u s ei tc o r r e s p o n d st oa
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7cups per day, and because this dose is intended for use
over an extended period of time, i.e. three years.
Of course, the mere act of taking a capsule two times
a day might discourage some individuals from perform-
ing an individual preventive plan, but in principle this
would be possible, and could be a recommendation for
a broader target audience.
There are some data indicating that the other poly-
phenols in green tea may also contribute to its beneficial
effects. Therefore we chose to use green tea extract con-
taining a defined amount of ECGC but also the other
polyphenols that are found in green tea.
We believe that a randomized controlled trial design is
the only appropriate method to perform such a preven-
tive trial, and justifies the efforts of such a trial. The
limitations of the trial are the relatively short time per-
iod for follow-up (three years is short compared to the
adenoma carcinoma sequence), the lack of a regular
adherence measurement (ECGC does not accumulate
and has a short half life, and therefore there is no long
term parameter for the intake of EGCG), and the risk of
a higher than presumed drop-out rate. However, the
beneficial safety profile of green tea extract, and the
widespread evidence on its cancer preventive potential,
justifies in our view a validation of this compound for
the nutriprevention of colorectal adenoma. Good acces-
sibility and low costs might render this neutraceutical a
top candidate for a wider use as food supplement in
colon cancer prevention.
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